X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DISHMAN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DISHMAN PHARMA DIVIS LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x 37.6 25.1 150.0% View Chart
P/BV x 6.1 3.3 182.4% View Chart
Dividend Yield % 0.7 0.7 110.7%  

Financials

 DIVIS LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142374 305.0%   
Low Rs533129 413.6%   
Sales per share (Unadj.) Rs146.6197.8 74.1%  
Earnings per share (Unadj.) Rs33.021.2 155.8%  
Cash flow per share (Unadj.) Rs38.434.7 110.6%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.20.8 150.2%  
Book value per share (Unadj.) Rs222.8179.9 123.9%  
Shares outstanding (eoy) m265.4780.69 329.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.71.3 449.0%   
Avg P/E ratio x25.311.9 213.6%  
P/CF ratio (eoy) x21.87.2 300.9%  
Price / Book Value ratio x3.81.4 268.7%  
Dividend payout %30.39.4 320.9%   
Avg Mkt Cap Rs m222,31820,306 1,094.9%   
No. of employees `00010.80.8 1,298.2%   
Total wages/salary Rs m4,5615,355 85.2%   
Avg. sales/employee Rs Th3,616.019,252.7 18.8%   
Avg. wages/employee Rs Th423.86,459.5 6.6%   
Avg. net profit/employee Rs Th814.92,064.1 39.5%   
INCOME DATA
Net Sales Rs m38,91515,961 243.8%  
Other income Rs m1,134265 427.4%   
Total revenues Rs m40,04916,226 246.8%   
Gross profit Rs m12,6174,103 307.5%  
Depreciation Rs m1,4251,091 130.7%   
Interest Rs m13944 1.4%   
Profit before tax Rs m12,3132,334 527.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543624 568.2%   
Profit after tax Rs m8,7701,711 512.5%  
Gross profit margin %32.425.7 126.1%  
Effective tax rate %28.826.7 107.7%   
Net profit margin %22.510.7 210.2%  
BALANCE SHEET DATA
Current assets Rs m45,35111,018 411.6%   
Current liabilities Rs m6,5079,517 68.4%   
Net working cap to sales %99.89.4 1,061.5%  
Current ratio x7.01.2 602.0%  
Inventory Days Days127110 114.7%  
Debtors Days Days9535 273.1%  
Net fixed assets Rs m21,16016,304 129.8%   
Share capital Rs m531161 328.9%   
"Free" reserves Rs m58,62512,907 454.2%   
Net worth Rs m59,15614,516 407.5%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m67,83229,805 227.6%  
Interest coverage x926.83.5 26,701.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 107.1%   
Return on assets %12.98.9 145.3%  
Return on equity %14.811.8 125.8%  
Return on capital %20.817.5 118.9%  
Exports to sales %024.8 0.0%   
Imports to sales %21.83.7 583.6%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m8,485596 1,423.0%   
Fx inflow Rs m32,3594,952 653.5%   
Fx outflow Rs m9,042697 1,297.7%   
Net fx Rs m23,3174,255 548.0%   
CASH FLOW
From Operations Rs m7,7592,786 278.4%  
From Investments Rs m-4,783-1,529 312.8%  
From Financial Activity Rs m-3,142-941 333.8%  
Net Cashflow Rs m-166316 -52.5%  

Share Holding

Indian Promoters % 52.0 61.4 84.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 12.7 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 22.1 77.8%  
Shareholders   31,796 46,261 68.7%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ELDER PHARMA  FDC LTD.  SANOFI INDIA  UNICHEM LAB  ORCHID PHARMA LTD  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 24, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - BIOCON LTD COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS